With an additional revenue volume of US$220 million, more than 300 new employees, and therapeutic coverage in the fields of neurology, oncology, immunology, gastroenterology, rare diseases, and specialties, the acquisition expands and transforms Swixx BioPharma's market presence. The acquisition has immediate positive effects, creating a compelling one-stop shop and multiregional [...]
SWIXX BIOPHARMA EXPANDS TO LATIN AMERICA THROUGH STRATEGIC ACQUISITION AND MERGER WITH BIOPAS
